A Self-Navigated Educational Toolkit for Hematologic Cancer Patients, Caregivers, and Family/Friends Presented by Douglas Rupert, MPH RTI International.
1 Dose-adaptive study designs offer benefits for proof-of-concept / Phase IIa clinical trials, as well as raise issues for continued research OUTLINE:
TESARO VP, Pharmacovigilance Search & Selection
TESARO Chief Scientific Officer Search & Selection
TESARO VP of Medical Development Search & Selection
